clinical trial · NCT07489651
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Generalized Anxiety DisorderRE104 for InjectionPlacebo
brief summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
started
Apr 20, 2026
primary completion
Feb 1, 2027
completion
Apr 1, 2027
last updated
May 18, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol